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lacking. We wished to perform an unbi-
ased screen of transcriptional and lipido-
mic changes present in adipose tissue
associated with high-risk prostate cancer.
Methods: In 2011 we incorporated routine
adipose tissue collection into our existing
banking program, whereby fresh paired
periprostatic (anterior fat pad) and subcu-
taneous (abdominal wall) adipose tissue
was obtained from patients undergoing
prostatectomy for localized prostate can-
cer. Transcriptional changes in subcutane-
ous and periprostatic adipose tissue
associated with high (n = 24) and low
(n = 24) risk prostate cancer were deter-
mined using the Illumina HT12v4 Bead-
Chip. Differences in lipid speciation were
determined by LC/MS.
Results: To date, clinically annotated adi-
pose tissue samples have been collected on
>400 patients with a variety of risk profiles,
including post androgen deprivation ther-
apy. Principal component analysis of global
transcriptional profiles shows distinct clus-
tering of individual tissue types (SC vs PP,
high vs low), permitting the generation of a
highly accurate gene classifier (AUC >0.95)
based on as few as 5 transcripts. Significant
pathways enriched on GSEA include
Chemokine signaling (q = 0.006) and NF-
kappa B signaling pathway (q = 0.02).
Alterations in lipid speciation include sig-
nificant decreases in the concentration of
20:4 containing PC lipids.
Conclusions: Adipose tissue from patients
with high-risk prostate cancer demon-
strates distinct transcriptional and lipido-
mic profiles compared to patients with
low-risk disease. These changes are cur-
rently being orthogonally validated.
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Objective: Androgen targeted therapies
(ATT) are the most commonly used treat-
ments in prostate cancer (PCa).While
these therapies are initially effective, PCa
cells are able to activate adaptive response
pathways to survive these therapies and
progress to castration resistant PCa
(CRPC), a highly aggressive and ultimately
lethal stage of the disease. Neuroendocrine
transdifferentiation (NEtD), a process
whereby PCa cells gain neuroendocrine-
like characteristics, has been implicated in
the development of CRPC. The objective
of this study is to develop and characterise
models of therapy-induced NEtD to inves-
tigate the role of this adaptive plasticity in
the progression to CRPC.
Methods: NEtD was modelled in vitro
using LNCaP cells treated with ATTs,
including ARN509, Bicalutamide and En-
zalutamide. An LNCaP-derived model of
transient androgen receptor (AR) knock-
down using an inducible shRNA system
was also developed. Expression of neuro-
endocrine (NE) markers was assessed over
time using quantitative RT-PCR (qRT-
PCR), western blotting and FACS analysis.
The expression of NE markers was com-
pared to that of androgen regulated genes
and key drivers of additional adaptive
response pathways involved in PCa pro-
gression.
Results: Preliminary results have demon-
strated that androgen deprivation, ATTs
and AR knockdown induce varying tempo-
ral dynamics of NEtD in LNCaP cells. We
observe substantial overlap of therapy-
induced NEtD with additional adaptive
response pathways. A number of these genes
have been identified to have increased
expression in metastatic and CRPC samples.
Conclusions: As the incidence of NEtD
PCa is expected to rise rapidly through the
prolonged and sequential use of new
ATTs, there is an urgent clinical need to
identify the molecular mechanisms
involved in the development of NEtD
PCa. The development and characterisa-
tion of models of NEtD will allow for the
identification of novel biomarkers and
therapeutic targets for the clinical manage-
ment of advanced PCa.
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Objective: Recent reports provide evi-
dence that the epithelial-to-mesenchymal
transition (EMT) plays a key role in pros-
tate cancer (PCa) metastasis and therapy
resistance. We have recently identified the
cell surface receptor, Neuropilin-1 (NRP1)
to be increased during epithelial-mesen-
chymal transition (EMT) and this study
aims to determine whether the inhibition
of NRP1 will be a feasible therapeutic
strategy for blocking PCa metastasis and
therapy resistance.
Methods: qRT-PCR and western blotting
was used to determine the expression lev-
els of NRP1 in metastatic PCa cell lines.
NRP1 expression in clinical samples was
assessed using immunohistochemistry and
bioinformatic analysis of multiple indepen-
dent patient cohorts. RNAi approaches
were used to assess the functional role of
NRP1 in cell migration and invasion.
Results: NRP1 expression is elevated in
metastatic PCa cells. In vitro studies have
revealed the suppression of endogenous
NRP1 levels to significantly inhibit the
migratory and invasive behaviour of meta-
static PCa cells. Importantly, NRP1 is
increased in metastatic and therapy resis-
tant clinical PCa samples and high NRP1
levels to be associated with shorter time to
tumour relapse and shorter overall survival.
Conclusion: These results will provide the
preclinical data necessary to rationalise the
use of anti-NRP1 directed therapies for
clinical use in PCa patients. Pharmaceuti-
cal companies currently have antibody and
small molecule inhibitors under early
development as anticancer therapeutics.
This study will pave the way for larger
scale preclinical and clinical trials in the
PCa setting, with the ultimate goal of
accelerating the translation of these thera-
peutics into the clinic for PCa patients.
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